| |
This sounds like MBX vaccine
In 2013, the treatment window was extended by using an adenovirus-vectored consensus human IFNa (Ad-IFN) 23 administered with or before ZMAb 24. While the precise mechanism of protection remains unclear, it was shown that the monoclonal antibody-based treatment did not completely inhibit EBOV replication, leading to the development of a host immune response against EBOV 22, 24. In order to evaluate whether the immune response induced in NHPs during the ZMAb treatment and EBOV challenge is of sufficient quality to protect survivors against a subsequent exposure, ZMAb-treated animals that survived an initial challenge 22, 24 were rechallenged with EBOV either 10 or 13 weeks after the initial challenge and the memory immune responses were evaluated before and during the rechallenge.
Results
Introduction• Results• Discussion• Methods• References• Acknowledgements• Author information• Supplementary information Clinical findings In the first experiment, 6 cynomolgus macaques which survived a previous EBOV challenge by receiving a mouse MAb combination (ZMAb) beginning either 24 hours (A1–A4) or 48 hours (B1, B4) post-infection 22, were rechallenged 10 weeks after the initial challenge ( Figure 1A) to evaluate whether the immune response developed during treatment was protective without further intervention. The 6 treated survivors were rechallenged intramuscularly (IM) with 1000 PFU of EBOV and monitored daily for survival and clinical signs of disease over 28 days. All ZMAb-treated survivors survived the rechallenge ( Figure 1B). Since this was a pilot study, the controls used were from a parallel but different study using rhesus macaques and are only included here to show that the virus dose used to infect the cynomolgus macaques was indeed lethal. The normal time to death for cynomolgus macaques is generally 2–3 days earlier compared to rhesus macaques ( Figure 1C).
nature.com  |
